Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram in Localized Pancreatic Cancer
NCT05289830Phase 2
Key facts
- Status
- Terminated
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Countries
- 1
- Sponsor
- Case Comprehensive Cancer Center
- Modality
- Small Molecules
- Conditions
- major depressive disorder (MDD)
01
Overview
Phase 2, randomised, double-blind trial of Escitalopram oxalate oral solution in major depressive disorder (MDD) (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Change in the Rate of Depression at 12 weeks. Started Aug 2022; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Escitalopram
Participants receive Escitalopram
Placebo
Participants receive Placebo
03
Who it enrols
Adults aged 18-80 with localized pancreatic or periampullary adenocarcinoma planned for neoadjuvant chemotherapy, with ECOG PS 0-2, excluding those currently on psychiatric medications, with a history of bipolar disease, mania, seizure disorder, recent heart issues, or severe renal/hepatic impairment.
04
Endpoints
Primary
Change in the Rate of Depression
Secondary
Quality of Life Using FACT-Hep Survey
Beyond the preview
Go deeper on NCT05289830.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289830.